ClinicalTrials.gg
Active, not recruitingNCT05141201Updated Jun 17, 2026

SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

An observational study in Lupus Erythematosus, Systemic, sponsored by AstraZeneca. Active, not recruiting at 47 sites in Japan. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by AstraZeneca · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,620
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca — 19 open to participants now, 25 under way, 6 of them phase 3. Lupus Erythematosus, Systemic · AstraZeneca.

Enrollment
3rd of 19
1,620 · median 500
Started
2021
with 3 others
Observational
19 of 46
9 open now
Primary completion
2027-03
later than 4 of 24 live
Registered
18th of 46
by date

Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 3rd largest by enrollment of the 19 observational ones that give a count, is one of 4 that started in 2021, is one of 19 observational ones, reaches primary completion later than 4 of the 24 other live ones, and was the 18th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

19 of the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, or all of them as a file.
02

Study summary

To collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus in the real-world post-marketing setting.

Read the detailed description

The objective of the Specific Use Result Study is to collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus insufficiently responding to currently available treatment in the real-world post-marketing setting.

This investigation will be conducted to support the application for re-examination specified in Article 14-4 of the Pharmaceutical Affairs Law.

03

Conditions studied

  • Lupus Erythematosus, Systemic
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with systemic lupus erythematosus insufficiently responding to currently available treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

patients with systemic lupus erythematosus insufficiently responding to currently available treatment -

Exclusion criteria

Exclusion Criteria:

None

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,620 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of ADRs

    Incidence of ADRs related to Anifrolimab. Safety specification: Herpes zoster, serious infections, anaphylaxis, malignancy and reactivation of hepatitis B virus

    Time frame: from the baseline to 52 weeks

07

Study locations

47 sites
  • Research Site
    Aichi, Japan
  • Research Site
    Akita, Japan
  • Research Site
    Aomori, Japan
  • Research Site
    Chiba, Japan
  • Research Site
    Ehime, Japan
  • Research Site
    Fukui, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Fukushima, Japan
  • Research Site
    Gifu, Japan
  • Research Site
    Gunma, Japan
  • Research Site
    Hiroshima, Japan
  • Research Site
    Hokkaido, Japan
  • Research Site
    Hyōgo, Japan
  • Research Site
    Ibaraki, Japan
  • Research Site
    Ishikawa, Japan
  • Research Site
    Kagawa, Japan
  • Research Site
    Kagoshima, Japan
  • Research Site
    Kanagawa, Japan
  • Research Site
    Kochi, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Mie, Japan
  • Research Site
    Miyagi, Japan
  • Research Site
    Miyazaki, Japan
  • Research Site
    Nagano, Japan
  • Research Site
    Nagasaki, Japan
  • Research Site
    Nara, Japan
  • Research Site
    Niigata, Japan
  • Research Site
    Numakunai, Japan
  • Research Site
    Okayama, Japan
  • Research Site
    Okinawa, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Ōita, Japan
  • Research Site
    Saga, Japan
  • Research Site
    Saitama, Japan
  • Research Site
    Shiga, Japan
  • Research Site
    Shimane, Japan
  • Research Site
    Shizuoka, Japan
  • Research Site
    Tochigi, Japan
  • Research Site
    Tokushima, Japan
  • Research Site
    Tokyo, Japan
  • Research Site
    Tottori, Japan
  • Research Site
    Toyama, Japan
  • Research Site
    Wakayama, Japan
  • Research Site
    Yamagata, Japan
  • Research Site
    Yamaguchi, Japan
  • Research Site
    Yamanashi, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluatedas per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes,indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Mar 2027, 63 months after the start.

Of 112 observational studies under Lupus Erythematosus, Systemic, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 126. This study's planned 63 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2021
First posted
Dec 2, 2021
StartActual
Dec 21, 2021
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05141201
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Dec 21, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jun 17, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion